Track topics on Twitter Track topics that are important to you
UnitedHealth Group Inc. (NYSE:UNH) will remove Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY) and Neupogen filgrastim from Amgen Inc. (NASDAQ:AMGN) from its 2017 Prescription Drug List, substituting follow-on biologic Basaglar insulin glargine and biosimilar Zarxio filgrastim-sndz. The change will be effective on Jan. 1, 2017, for Neupogen, and on April 1, 2017, for Lantus.
The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) markets Zarxio, and Eli Lilly and Co. (NYSE:LLY) markets Basaglar.
In a webcast describing the changes, UnitedHealth said unchecked price increases for Lantus led it to seek alternatives for the diabetes treatment. In a statement, Sanofi said it was "disappointed" by the exclusion. The company expects to maintain its current global diabetes guidance of a 4-8% annual decline from 2015-18.
Last month, CVS Health Corp. (NYSE:CVS) said it will remove both Lantus and Neupogen from its standard formulary for 2017, along with 33 other drugs. The CVS formulary also substituted Basaglar and Zarxio (see BioCentury Extra, Aug. 2).
Additional exclusions from UnitedHealth include chronic myelogenous leukemia (CML) drug Gleevec imatinib from Novartis and OxyContin oxycodone from Purdue Pharma L.P. (Stamford, Conn.). UnitedHealth will substitute a generic imatinib, and will cover Xtampza ER oxycodone extended-release from Collegium Pharmaceutical Inc. (NASDAQ:COLL) in place of OxyContin. CVS also will no longer cover Gleevec in 2017.
Original Article: UnitedHealth excludes Lantus, Neupogen from 2017 drug listNEXT ARTICLE
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...